Publications
Detailed Information
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Modi, Shanu | - |
dc.contributor.author | Jacot, William | - |
dc.contributor.author | Yamashita, Toshinari | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Vidal, Maria | - |
dc.contributor.author | Tokunaga, Eriko | - |
dc.contributor.author | Tsurutani, Junji | - |
dc.contributor.author | Ueno, Naoto T. | - |
dc.contributor.author | Prat, Aleix | - |
dc.contributor.author | Chae, Yee Soo | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Niikura, Naoki | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Xu, Binghe | - |
dc.contributor.author | Wang, Xiaojia | - |
dc.contributor.author | Gil-Gil, Miguel | - |
dc.contributor.author | Li, Wei | - |
dc.contributor.author | Pierga, Jean-Yves | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Moore, Halle C F | - |
dc.contributor.author | Rugo, Hope S. | - |
dc.contributor.author | Yerushalmi, Rinat | - |
dc.contributor.author | Zagouri, Flora | - |
dc.contributor.author | Gombos, Andrea | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Liu, Qiang | - |
dc.contributor.author | Luo, Ting | - |
dc.contributor.author | Saura, Cristina | - |
dc.contributor.author | Schmid, Peter | - |
dc.contributor.author | Sun, Tao | - |
dc.contributor.author | Gambhire, Dhiraj | - |
dc.contributor.author | Yung, Lotus | - |
dc.contributor.author | Wang, Yibin | - |
dc.contributor.author | Singh, Jasmeet | - |
dc.contributor.author | Vitazka, Patrik | - |
dc.contributor.author | Meinhardt, Gerold | - |
dc.contributor.author | Harbeck, Nadia | - |
dc.contributor.author | Cameron, David A. | - |
dc.date.accessioned | 2022-10-11T01:16:18Z | - |
dc.date.available | 2022-10-11T01:16:18Z | - |
dc.date.created | 2022-07-27 | - |
dc.date.created | 2022-07-27 | - |
dc.date.created | 2022-07-27 | - |
dc.date.created | 2022-07-27 | - |
dc.date.created | 2022-07-27 | - |
dc.date.created | 2022-07-27 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.citation | New England Journal of Medicine, Vol.387 No.1, pp.9-20 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185739 | - |
dc.description.abstract | Copyright © 2022 Massachusetts Medical Society.BACKGROUND: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers. METHODS: We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. The primary end point was progression-free survival in the hormone receptor-positive cohort. The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients. RESULTS: Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor-positive disease and 63 (11.3%) had hormone receptor-negative disease. In the hormone receptor-positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician's choice group (hazard ratio for disease progression or death, 0.51; P<0.001), and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P = 0.003). Among all patients, the median progression-free survival was 9.9 months in the trastuzumab deruxtecan group and 5.1 months in the physician's choice group (hazard ratio for disease progression or death, 0.50; P<0.001), and overall survival was 23.4 months and 16.8 months, respectively (hazard ratio for death, 0.64; P = 0.001). Adverse events of grade 3 or higher occurred in 52.6% of the patients who received trastuzumab deruxtecan and 67.4% of those who received the physician's choice of chemotherapy. Adjudicated, drug-related interstitial lung disease or pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events. CONCLUSIONS: In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.). | - |
dc.language | 영어 | - |
dc.publisher | Massachusetts Medical Society | - |
dc.title | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1056/NEJMoa2203690 | - |
dc.citation.journaltitle | New England Journal of Medicine | - |
dc.identifier.wosid | 000806835900001 | - |
dc.identifier.scopusid | 2-s2.0-85133263146 | - |
dc.citation.endpage | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 9 | - |
dc.citation.volume | 387 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ANTIBODY-DRUG CONJUGATE | - |
dc.subject.keywordPlus | DS-8201A | - |
dc.subject.keywordPlus | ERIBULIN | - |
dc.subject.keywordPlus | PALBOCICLIB | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | LETROZOLE | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.